Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms

Publisher： John Wiley & Sons Inc

E-ISSN： 1096-8652|93|3|330-338

ISSN： 0361-8609

Source： AMERICAN JOURNAL OF HEMATOLOGY, Vol.93, Iss.3, 2018-03, pp. : 330-338

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Favorable prognosis of biallelic CEBPA gene mutations in acute myeloid leukemia patients: a meta‐analysis

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 94, Iss. 5, 2015-05 ,pp. : 439-448

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment with FLT3 inhibitor in patients with FLT3‐mutated acute myeloid leukemia is associated with development of secondary FLT3–tyrosine kinase domain mutations

By  

CANCER, Vol. 120, Iss. 14, 2014-07 ,pp. : 2142-2149

John Wiley & Sons Inc

Access to resources Recommend Favorite

Genetic Mutations in Patients with Acute Myeloid Leukemia and Leukostasis

By  

Acta Haematologica, Vol. 130, Iss. 2, 2013-03 ,pp. : 95-97

Karger

Access to resources Recommend Favorite

G‐CSF Priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 4, 2015-04 ,pp. : 295-300

John Wiley & Sons Inc

Access to resources Recommend Favorite

Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 5, 2015-05 ,pp. : E77-E79

John Wiley & Sons Inc

Access to resources Recommend Favorite